Parathyroid Flashcards
when is parathyroid hormone secreted
when calcium is low, PTH stimulated. when calcium rises, PTH is suppressed
classical actions of PTH
release Ca from bone, reabsorb Ca in kidneys. this leads to synth of 1,25 OH2 D3 and absorption of Ca and PO4 in small intestine.
what accounts for most of the protein binding of calcium?
albumin! need to use a formula to correct calcium level.
corrected total calcium (mg/dL) = measured total calcium + 0.8X [4- measured albumin]
phosphorus
levels influenced by PTH and 1,25(OH)2D. proximal tubule reabsorption increased by phosphate depletion, hyperparathyroidism, and hypocalcemia. excretion increased by PTH, PTHrP, hypercalcemia, hypokalemia, hypomagnesemia, calcitonin, glucocorticoids and diuretics
magnesium
necessary for release of PTH and for the action of the hormone of its target tissues. primarily renally excreted. some drugs, furosemide and cisplatin, inhibit magnesium reabsorption at the loop of henle.
vitamin D
maintains normal serum calcium level by increasing intestinal absorption of dietary calcium and stimulating bone cells to become osteoclasts.
hypercalcemia
most common causes are hyperparathyroid or malignancy. if primary hyperparathyroid, PTH level is high or normal.
primary hyperparathyroidism
results from excessive PTH secretion. usually caused by an adenoma. diagnosed with an elevated calcium, elevated or normal PTH, may see low phosphorus, elevated urine calcium.
treatment of primary hyperparathyroidism
cured when abnormal tissue is removed. surgery usually good. those with mild disease or asymptomatic could be followed.
medical treatment of primary hyperparathyroidism
adequate hydration and ambulation. moderate calcium intake. bisphosphonates may be useful to treat low bone density. calcomimetics can reduce PTH and Ca levels. sensipar is FDA approved for hyperparathyroid in renal disease and parathyroid carcinoma and in ppl who refuse surgery
treatment of hypercalcemia
diagnose and treat underlying cause and mechanism. mild (14): can be life threatening, rquires immediate treatment, prognosis may be poor if from malignancy
bisphosphonates
inhibits bone resorption, need to be given IV for this. pamidronate and zoledronic acid most common. does not work immediately. can cause fever/flu like symptoms.
calcitonin
modest yet rapid lowering of Ca. increases urinary calcium excretion, inhibits bone resorption. good for acute setting
secondary hyperparathyroidism
PTH secreted in response to perceived low calcium concentration. occurs in renal disease due to phosphate retention and lack of 1-alpha hydroxylase activity, resulting in a deficient 1,25 (OH)2D. vitamin D deficiency can be a cause.
tertiary hyperparathyroidism
result of parathyroid glands becoming autonomous after prolonged secondary hyperparathyroidism. calcium is elevated.
hypocalcemia
can arise from destruction or failuure of the parathyroid glands or inactivity of PTH at target tissues. hypocalcemic disorders can be categorized based upon low or elevated PTH levels.
chronic renal failure and hypocalcemia
most common cause of hypocalcemia where phosphorus, PTH, and creatinine levels are high. limited excretion of Phosphorus and diminished hydroxylation of 1,25 vitamin D causes decreased Ca absorption and decreased mobilization from bone which causes PTH secretion. treat with calcitriol or other vitamin D analogs. can use phosphate binders or calcimimetics
hypoparathyroidism
when PTH produced is insufficient to maintain serum calcium levels or is unable ot function properly at target tissues. usually low Ca, high phosphorus, and low PTH.
25-hydroxyvitamin D as a pharm agent
aggressive repletion necessary in patients with vit D deficiency secondary to dietary insufficiency. Vit D deficiency can present with a low Ca and phosph, high PTH and/or low AP, low urine Ca.
hypophosphatemia
caused by decreased intestinal absorption, increased urinary losses, or transcellular shift. treat with replacing phosphorus and calcitriol
bisphosphates to treat osteoporosis
reduce osteoclast bone resorption with an increase in BMD and a decrease in fracture risk. alendronate, risedronate, and ibandronate. can lead to GI irritation at esophagus. take when fasting.
SERMs for treatment of osteoporosis
selective estrogen receptor modulators. use in postmenopausal women. estrogen like compounds, cause decrease in bone resorption. doesnt have same undesireable effects as estrogen. raloxifene.
teriparatide for osteoporosis
only anabolic agent for osteoporosis. PTH analog. reserved for patients at high risk of fracture. given as daily shot. up to 2 years.
denosumab for osteoporosis
RANK ligand inhibitor. antiresorptive. very well tolerated, can lead to skin infections or hypocalcemia